ClinicalTrials.gg
CompletedNCT06683612Updated Aug 6, 2025

PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

A Phase 1 interventional study of PIPE-791 in Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis and Multiple Sclerosis, sponsored by Contineum Therapeutics. Completed at 1 site in United Kingdom. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Contineum Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom — 14 open to participants now, 22 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · United Kingdom.

Enrollment
74th of 83
16 · median 109
Started
2024
with 8 others
Phase 1
15 of 103
none open now
Registered
89th of 103
by date

Among the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, this one is the 74th largest by enrollment of the 83 interventional ones that give a count, is one of 9 that started in 2024, is one of 15 in phase 1, and was the 89th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

14 of the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF). The purpose of this study is to find out how much of the study drug gets into the brain and lung, and what the side effects and blood levels of the study drug are in healthy volunteers and patients.

Participants will:

  • Take a single dose of the study drug
  • Give many samples of blood and urine
  • Have multiple PET scans
03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)
  • Idiopathic Pulmonary Fibrosis
  • Multiple Sclerosis
  • Multiple Sclerosis, MS
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Progressive
  • Multiple Sclerosis, Secondary Progressive
  • Healthy
  • Healthy Volunteers

Keywords

  • remyelination
  • MS
  • multiple sclerosis
  • PrMS
  • PPMS
  • SPMS
  • primary progressive MS
  • primary progressive multiple sclerosis
  • secondary progressive multiple sclerosis
  • secondary progressive MS
  • LPA1
  • PMS
  • idiopathic pulmonary fibrosis
  • IPF
  • neuroinflammation
  • PIPE-791
  • demyelinating diseases
  • autoimmune diseases
  • pathologic processes
  • demyelinating autoimmune diseases, CNS
  • autoimmune diseases of the nervous system
  • nervous system diseases
  • immune diseases
  • sclerosis
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria

  • All parts: male volunteers or female volunteers of non-; agree to follow the requirements of the trial, and able to give fully informed written consent.
  • Part A: normotensive volunteers, deemed healthy on the basis of a clinical history, medical examinations, , vital signs, and laboratory tests of blood and urine.
  • Part B: volunteers with a diagnosis of PPMS or SPMS by a neurologist, according to the 2017 Revised McDonald Criteria.
  • Part C: volunteers with a diagnosis of IPF by a pulmonologist, according to the 2018 American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) Clinical Practice Guideline, within 7 years before screening.

Main Exclusion Criteria

  • Positive tests for and C, (HIV)
  • Severe adverse reaction to any drug; sensitivity to trial medication
  • Drug or alcohol abuse
  • Smoking or use of tobacco or nicotine-containing products from 7 days before screening, until the final visit
  • Use of a prescription medicine (except hormone replacement therapy [HRT] in women, and medications for participants with PrMS and IPF at the discretion of the investigator), or any substance known to interact with cytochrome p450 (CYP)3A enzymes (including St. John's wort and foodstuffs such as grapefruit juice) during the 28 days before the first dose of PIPE-791
  • Use of any other over-the-counter medicine, with the exception of acetaminophen (paracetamol) during the 7 days before the first dose of PIPE-791, or received vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), during the 7 days before screening
  • Participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the 3 months before the baseline PET scan
  • Vital signs or ECGs outside the acceptable range at screening
  • abnormal findings at the screening assessments, including C-SSRS and MRI (Parts A [brain PET imaging arm] and B only)
  • Acute or chronic illness (except PrMS and IPF in Parts B and C, respectively)
  • Clinically relevant abnormal medical history or concurrent medical condition
  • Possibility that volunteer will not cooperate
  • to MRI (Parts A [brain PET imaging arm] and B only), computed tomography (CT), PET, or arterial cannulation procedures
  • Significant exposure to research-related radiation or other radiation exposure (exceeding 10 mSv when added to exposure from this study) within the previous 12 months
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Healthy volunteers, brain PET imaging

    Drug: PIPE-791

  • Experimental
    Healthy volunteers, lung PET imaging

    Drug: PIPE-791

  • Experimental
    Volunteers with PrMS

    Drug: PIPE-791

  • Experimental
    Volunteers with IPF

    Drug: PIPE-791

Interventions

  • Subjects will receive a single oral dose of PIPE-791.

06

What researchers measure

Primary outcomes

  1. LPA1 occupancy as determined by regional total volume of distribution (VT) at each brain scan.

    Time frame: Baseline to up to 28 days post-dose

  2. LPA1 occupancy as determined by regional total volume of distribution (VT) at each lung scan.

    Time frame: Baseline to up to 28 days post-dose

Secondary outcomes

  1. The relationship between PIPE-791 plasma concentration and brain and lung LPA1 occupancy.

    Time frame: Baseline to up to 28 days post-dose

  2. The PIPE-791 EC50 (i.e., the plasma concentration of PIPE-791 associated with 50% occupancy of LPA1) in the brain and lungs.

    Time frame: Baseline to up to 28 days post-dose

  3. Pharmacokinetics (PK): blood concentration levels of PIPE-791

    Time frame: Baseline to up to 28 days post-dose

  4. Safety and tolerability: Treatment-Emergent Adverse Events (TEAE)

    Time frame: Baseline to up to 32 days post-dose

07

Study locations

1 site
  • Hammersmith Medicines Research
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jun 2025, 5 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 12, 2024
StartActual
Dec 9, 2024
Primary completionActual
Jun 4, 2025
CompletionActual
Jun 12, 2025
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06683612
Lead sponsor
Contineum Therapeutics
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Dec 9, 2024
Primary completion
Jun 4, 2025
Completion
Jun 12, 2025
Last update
Aug 6, 2025

Study contacts

Stephen Huhn, MD
study director · Contineum Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PIPE-791

Start the discussion